

**AMENDMENTS TO THE CLAIMS:**

Amend the claims as follows:

Claims 1-21. (Canceled)

~~1~~<sup>1</sup>22. (Currently Amended) An antibody conjugate, comprising a humanized antibody or an antibody fragment thereof which is conjugated with a therapeutic agent, wherein the humanized antibody or the antibody fragment thereof specifically binds to ganglioside GD3 and comprises:

the H chain V region having the amino acid sequence of SEQ ID NO:9; and

the L chain V region having the amino acid sequence of SEQ ID NO:54

~~The antibody conjugate according to claim 1, wherein the humanized antibody comprises:~~

~~the H chain V region having the amino acid sequence represented by SEQ ID NO:9; and~~

~~the L chain V region having the amino acid sequence represented by SEQ ID NO:54.~~

~~2~~<sup>2</sup>23. (Currently Amended) An antibody conjugate, comprising a humanized antibody  
~~The antibody conjugate according to claim 1, wherein the humanized antibody is an~~  
~~antibody produced by a transformant KM8871 (FERM BP-6790) or an antibody~~  
<sup>the transformant</sup>

fragment thereof which is conjugated with a therapeutic agent, wherein the humanized antibody or the antibody fragment thereof specifically binds to ganglioside GD3.

Claims 24-31. (Canceled)

~~3~~<sup>1</sup>~~2~~. (Currently Amended) The antibody conjugate according to claim ~~22~~<sup>1</sup>[[1]], wherein the antibody fragment comprises:

the H chain V region having the amino acid sequence of ~~represented by~~ SEQ ID NO:9; and

the L chain V region having the amino acid sequence of ~~represented by~~ SEQ ID NO:54.

Claims 33-35. (Canceled)

~~4~~<sup>1</sup>~~36~~. (Currently Amended) The antibody conjugate according to claim ~~[[1]]22~~<sup>1</sup>, wherein the therapeutic agent is a cytokine.

~~5~~<sup>4</sup>~~37~~. (Previously Presented) The antibody conjugate according to claim ~~36~~<sup>4</sup>, wherein the cytokine is human interleukin-2 (hIL-2).

Claims 38-39. (Canceled)

~~6~~<sup>4</sup>~~40~~. (Currently Amended) An antibody conjugate, comprising a humanized antibody or an antibody fragment thereof which is conjugated with a therapeutic agent, wherein the humanized antibody or the antibody fragment thereof specifically binds to ganglioside GD3. ~~The antibody conjugate according to claim 37, wherein the antibody~~

~~conjugate comprises a humanized antibody~~ is produced by transformant KM8871  
(FERM BP-6790) and the therapeutic agent is hIL-2.

~~7~~ ~~41.~~ (Currently Amended) An antibody conjugate, comprising a humanized-antibody  
or an antibody fragment thereof which is conjugated with ~~The antibody conjugate~~  
~~according to claim 37, wherein the antibody conjugated with hIL-2 comprises:~~

~~the,~~ wherein the humanized antibody or the antibody fragment thereof specifically  
binds to ganglioside GD3 and comprises:

the H chain V region having the amino acid sequence of ~~represented by~~ SEQ ID  
NO:9; and

the L chain V region having the amino acid sequence of ~~represented by~~ SEQ ID  
NO:54,

wherein the H chain V region conjugated with hIL-2 has the amino acid sequence  
of ~~represented by~~ SEQ ID NO:53.

Claims 42-47. (Canceled)

~~8~~ ~~48.~~ (Currently Amended) A humanized antibody or an antibody fragment thereof  
which specifically binds to ganglioside GD3 and comprises:

~~[[an]]~~ the H chain V region having the amino acid sequence of ~~represented by~~ SEQ  
ID NO:9; and

~~[[an]]~~the L chain V region having the amino acid sequence of SEQ ID NO:10 in which at least one or more amino acid residue selected from 41<sup>st</sup> position Gly, 44<sup>th</sup> position Pro, 83<sup>rd</sup> position Phe and 87<sup>th</sup> position Tyr ~~represented by SEQ ID NO:10~~ is replaced with Asp, Val, Ile and Phe, respectively.

Claims 49-57. (Canceled)

~~10~~ 58. (Currently Amended) The humanized antibody KM8871 or the antibody fragment thereof according to claim ~~48~~ <sup>8</sup> or ~~65~~ <sup>9</sup> or 63, wherein the humanized antibody is ~~an antibody~~ produced by ~~a transformant~~ <sup>the transformant</sup> KM8871 (FERM BP-6790).

Claims 59-61. (Canceled)

~~11~~ 62. (Currently Amended) A transformant KM8871 (FERM BP-6790) which produces the humanized antibody according to claim ~~48~~ <sup>8</sup> or ~~65~~ <sup>9</sup> or 63.

Claims 63-64. (Canceled)

~~9~~ 65. (Currently Amended) The humanized antibody or the antibody fragment thereof according to claim ~~48~~ <sup>8</sup> or 63, wherein the antibody fragment comprises:

the H chain V region having the amino acid sequence of ~~represented by~~ SEQ ID NO:9; and

the L chain V region having the amino acid sequence of ~~represented by~~ SEQ ID NO:54.

Claims 66-68. (Canceled)

12~~69~~<sup>6</sup>. (Previously Presented) The antibody conjugate of claim ~~40~~<sup>6</sup>, wherein the  
antibody conjugate is ~~an antibody conjugate~~ <sup>the transformant</sup> produced by a transformant KM8871hIL2  
(FERM BP-6791).